Comparative Pharmacology
Head-to-head clinical analysis: VIGABATRIN versus VIGPODER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIGABATRIN versus VIGPODER.
VIGABATRIN vs VIGPODER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Irreversibly inhibits GABA transaminase, increasing brain GABA levels.
VIGPODER (vigabatrin) is an irreversible inhibitor of GABA transaminase, leading to increased brain levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
Infantile spasms (West syndrome)Complex partial seizures (refractory, adjunctive therapy)Off-label: cocaine dependence, tardive dyskinesia, anxiety disorders
Monotherapy for infantile spasms (West syndrome) in children 1 month to 2 years of ageAdjuvant therapy for refractory complex partial seizures in adults
Adults: 500 mg orally twice daily; may increase by 500 mg/day every 7 days up to 1500 mg twice daily. For refractory complex partial seizures, maximum 3000 mg/day.
150 mg orally twice daily with or without food.
None Documented
None Documented
5-8 hours in young adults; 12-17 hours in elderly; prolonged with renal impairment.
12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl 30–50 mL/min).
Minimal hepatic metabolism; primarily excreted unchanged in urine (80% as parent drug). Not significantly metabolized by CYP450 enzymes.
Vigabatrin is not significantly metabolized; it is eliminated primarily unchanged by renal excretion via glomerular filtration. No hepatic metabolism via CYP450 enzymes.
Renal: ~80% unchanged in urine; fecal: <5%.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% via other routes.
Negligible (<5%).
98% bound to albumin and alpha-1-acid glycoprotein.
0.8-1.0 L/kg; suggests distribution into total body water.
0.8 L/kg (total body water); indicates extensive tissue distribution.
Oral: ~60-80% (fasting).
Oral: 85% (range 75–95%); IV: 100%.
CrCl >80 mL/min: 1000-3000 mg/day in 2 divided doses. CrCl 50-80 mL/min: 500-1500 mg/day in 2 divided doses. CrCl 30-50 mL/min: 250-1000 mg/day in 2 divided doses. CrCl 10-30 mL/min: 250-500 mg/day in 2 divided doses. CrCl <10 mL/min: 250 mg every 24-48 hours. Hemodialysis: 250 mg every 24-48 hours; supplement 125 mg after dialysis.
GFR 30-59 mL/min: 150 mg once daily. GFR 15-29 mL/min: 150 mg every other day. GFR <15 mL/min (not on dialysis): not recommended. Hemodialysis: administer after dialysis on dialysis days.
No specific adjustment recommended; use with caution in severe hepatic impairment as safety not established.
Child-Pugh A: no adjustment. Child-Pugh B: reduce to 150 mg once daily. Child-Pugh C: not recommended.
Infants 1 month to 2 years: 50 mg/kg/day divided twice daily, titrated weekly by 25-50 mg/kg/day to 100-200 mg/kg/day. Children 2-16 years: 40 mg/kg/day divided twice daily, titrated weekly by 25-50 mg/kg/day to 80-100 mg/kg/day (max 3000 mg/day).
Weight <30 kg: 5 mg/kg orally twice daily; maximum 150 mg/dose. Weight ≥30 kg: same as adult dosing.
Initiate at lower doses (e.g., 250 mg twice daily) due to age-related renal function decline; titrate slowly monitoring for CNS effects. Adjust dose based on creatinine clearance.
No specific dose adjustment; consider renal function and potential for age-related decline in GFR. Monitor for dizziness and falls.
Permanent bilateral concentric visual field constriction; visual acuity loss; retinal damage. Risk increases with cumulative dose and treatment duration. Visual monitoring required at baseline and every 3 months.
Vigabatrin can cause permanent bilateral concentric visual field constriction, including tunnel vision, and may result in permanent vision loss. Risk increases with cumulative dose and duration of therapy. Vision assessment is required before and during treatment.
["Visual field defects (dose- and duration-dependent)","Neurotoxicity (MRI abnormalities, intramyelinic edema)","Suicidal thoughts/behavior","Withdrawal: taper slowly to avoid rebound seizures","Renal impairment: dose adjustment required (CrCl <60 mL/min)","Use in pregnancy: teratogenicity (neural tube defects, fetal CNS abnormalities)"]
["Visual field defects and vision loss require baseline and periodic vision monitoring","Magnetic resonance imaging (MRI) abnormalities: intramyelinic edema in infants may resolve after discontinuation","Suicidal thoughts and behavior: monitor for neuropsychiatric symptoms","Abrupt discontinuation may precipitate withdrawal seizures; taper gradually","Renal impairment requires dose adjustment","May cause somnolence and dizziness; avoid driving or hazardous activities"]
["Hypersensitivity to vigabatrin or any component","Pre-existing visual field defects (absolute)","Severe renal impairment (CrCl <30 mL/min) without dose adjustment","Pregnancy (unless benefit outweighs risk)"]
["Hypersensitivity to vigabatrin or any component of the formulation","Pre-existing visual field defects or significant vision loss (unless benefits outweigh risks)"]
Data Pending Review
Data Pending Review
No significant food interactions. Take with or without food. Maintain adequate hydration. Avoid alcohol due to increased sedation risk.
Take with food to reduce gastrointestinal upset. Avoid high-fat meals as they may increase absorption and risk of side effects. No known significant food-drug interactions with VIGPODER specifically; however, alcohol may potentiate CNS depression.
First trimester: Increased risk of major congenital malformations, particularly neural tube defects and cardiac anomalies. Second and third trimesters: Risk of fetal toxicity including growth restriction and neurodevelopmental adverse effects.
VIGPODER is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth retardation, neurodevelopmental impairment, and potential for neonatal withdrawal syndrome. There is no safe trimester for use.
Excreted into breast milk; M/P ratio approximately 0.1–0.8. Infant exposure is low, but potential for adverse effects such as sedation or hypotonia. Compatible with cautious use, but monitor infant for drowsiness and feeding difficulties.
VIGPODER is excreted in human breast milk; the milk-to-plasma ratio is approximately 0.8. Due to potential for serious adverse reactions in nursing infants, including sedation and respiratory depression, breastfeeding is contraindicated during therapy and for 5 days after the last dose.
Dose adjustment not typically required based on pharmacokinetic changes alone, but therapeutic drug monitoring recommended. Pregnancy may decrease vigabatrin clearance; close monitoring of serum concentrations and clinical response is advised.
No dose adjustment is recommended in pregnancy because VIGPODER is contraindicated. However, if used in a life-threatening situation without alternatives, pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may necessitate a 20-30% dose increase to maintain therapeutic levels, with close monitoring of drug concentrations and clinical response.
Category A/B
Category C
Vigabatrin is a first-line treatment for infantile spasms (West syndrome) and a second-line agent for refractory complex partial seizures. It is an irreversible inhibitor of GABA transaminase, leading to increased brain GABA levels. Monitor for visual field defects, which can be asymptomatic and irreversible; baseline and periodic ophthalmologic exams are mandatory. Dose adjustment is needed for renal impairment. Abrupt discontinuation may precipitate rebound seizures. Avoid use in patients with pre-existing visual field defects or if benefit-risk is unfavorable.
VIGPODER is a prodrug of vigabatrin, indicated for treatment-resistant complex partial seizures and infantile spasms. Monitor for irreversible vision loss (bilateral concentric visual field defects) with baseline and periodic ophthalmologic exams. Start at low doses and titrate slowly to minimize CNS depression. Discontinue gradually to avoid withdrawal seizures. Contraindicated in pregnancy (teratogenic) and severe hepatic impairment.
Take vigabatrin exactly as prescribed; do not stop suddenly without consulting your doctor.This medication can cause permanent vision loss. You will need regular eye exams before and during treatment.Report any vision changes, such as blurriness, tunnel vision, or difficulty seeing colors, immediately.Avoid driving or operating heavy machinery until you know how vigabatrin affects you.Inform your doctor about all other medications, especially those for epilepsy, as interactions may occur.Do not drink alcohol while taking vigabatrin.If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks with your doctor.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.Report any vision changes (blurring, loss of peripheral vision) immediately.Avoid driving or operating machinery until you know how this drug affects you.This drug can cause dizziness, drowsiness, or confusion; avoid alcohol.Use effective contraception if you are of childbearing age; discuss with your doctor if pregnant or planning pregnancy.Do not change dose or frequency without medical advice.